Open AccessChange in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
Author(s) -
Hidekatsu Kuorda,
Tamami Abe,
Yoshitaka Fujiwara,
Takuya Okamoto,
Miki Yonezawa,
Hiroki Sato,
Kei Endo,
Takayoshi Oikawa,
Kei Sawara,
Yasuhiro Takikawa
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i19.2365
Subject(s) - lenvatinib , medicine , hepatocellular carcinoma , area under the curve , response evaluation criteria in solid tumors , receiver operating characteristic , biomarker , contrast enhanced ultrasound , radiology , oncology , perfusion , sorafenib , nuclear medicine , urology , ultrasound , gastroenterology , phases of clinical research , clinical trial , biochemistry , chemistry
Lenvatinib is one of the rst-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imaging biomarkers of lenvatinib efficacy.